SELLAS Life Sciences (SLS) Equity Ratio (2019 - 2024)
SELLAS Life Sciences (SLS) has disclosed Equity Ratio for 9 consecutive years, with 0.6 as the latest value for Q3 2024.
- On a quarterly basis, Equity Ratio changed N/A to 0.6 in Q3 2024 year-over-year; TTM through Sep 2024 was 0.6, a N/A change, with the full-year FY2023 number at 1.28, down 653.7% from a year prior.
- Equity Ratio was 0.6 for Q3 2024 at SELLAS Life Sciences, up from 0.19 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.77 in Q4 2021 to a low of 1.28 in Q4 2023.
- A 5-year average of 0.36 and a median of 0.48 in 2022 define the central range for Equity Ratio.
- Peak YoY movement for Equity Ratio: soared 65.52% in 2020, then crashed 653.7% in 2023.
- SELLAS Life Sciences' Equity Ratio stood at 0.61 in 2020, then increased by 27.53% to 0.77 in 2021, then crashed by 70.09% to 0.23 in 2022, then plummeted by 653.7% to 1.28 in 2023, then skyrocketed by 146.75% to 0.6 in 2024.
- Per Business Quant, the three most recent readings for SLS's Equity Ratio are 0.6 (Q3 2024), 0.19 (Q2 2024), and 1.28 (Q4 2023).